Quatech is a specialist subsidiary of Gorgio International Holding, focused on advanced biotechnology, organic pharmaceuticals, and life-science innovation. The company brings together world-leading researchers, scientists, and inventors from global universities and research centres to translate scientific discovery into knowledge-based production. Quatech supports and invests in technologies for pharmaceutical and food industries by forming research and development teams around the world and applying their ideas to real-world community challenges. In its first phase, Quatech has successfully registered and produced wound-healing products for diabetic foot ulcers, bedsores, and burn ulcers, as well as medical and nutritional supplements with anti-cancer and anti-aging properties. Another significant area of activity is Quatech’s work in venom-derived therapeutics, producing animal-venom based compounds for anti-rheumatoid and antidote applications, and designing shuttle drugs for central nervous system disorders such as multiple sclerosis, Parkinson’s, Alzheimer’s, and Schwann-cell tumors. The company also maintains the scientific, economic, and international infrastructure to support inventions and researchers through partnerships, service purchases, and contractual cooperation in implementing scientific and technological ideas.
